Think Globally, Act Globally: An Epidemiologist's Perspective on
  Instrumental Variable Estimation by Swanson, Sonja A. & Hernán, Miguel A.
ar
X
iv
:1
41
0.
04
77
v1
  [
sta
t.M
E]
  2
 O
ct 
20
14
Statistical Science
2014, Vol. 29, No. 3, 371–374
DOI: 10.1214/14-STS491
Main article DOI: 10.1214/14-STS480
c© Institute of Mathematical Statistics, 2014
Think Globally, Act Globally:
An Epidemiologist’s Perspective
on Instrumental Variable Estimation
Sonja A. Swanson and Miguel A. Herna´n
We appreciated Imbens’ summary and reflections
on the state of instrumental variable (IV) methods
from an econometrician’s perspective. His review
was much needed as it clarified several issues that
have been historically a source of confusion when
individuals from different disciplines discussed IV
methods.
Among the many topics covered by Imbens, we
would like to focus on the common choice of the
local average treatment effect (LATE) over the
“global” average treatment effect (ATE) in IV anal-
yses of epidemiologic data. As Imbens acknowledges,
this choice of the LATE as an estimand has been
contentious (Angrist, Imbens and Rubin (1996);
Robins and Greenland (1996); Deaton (2010); Im-
bens (2010); Pearl (2011)). Several authors have
questioned the usefulness of the LATE for inform-
ing clinical practice and policy decisions, because it
only pertains to an unknown subset of the popula-
tion of interest: the so-called “compliers.” To make
things worse, many studies do not even report the
expected proportion of compliers in the study popu-
lation (Swanson and Herna´n, 2013). Other authors
have wondered whether the LATE is advocated for
simply because of the relatively weaker assump-
tions required for its identification, analogous to the
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drunk who stays close to the lamp post and declares
whatever he finds under its light is what he was look-
ing for all along (Deaton, 2010).
Here, we explore the limitations of the LATE in
the context of epidemiologic and public health re-
search. First we discuss the relevance of LATE as
an effect measure and conclude that it is not our
primary choice. Second, we discuss the tenability of
the monotonicity condition and conclude that this
assumption is not a plausible one in many common
settings. Finally, we propose further alternatives to
the LATE, beyond those discussed by Imbens, that
refocus on the global ATE in the population of in-
terest.
1. RELEVANCE OF A LOCAL AVERAGE
TREATMENT EFFECT IN EPIDEMIOLOGIC
RESEARCH
Some authors claim the LATE is actually what we
are primarily interested in, even if the “compliers”
are not identifiable. A common argument is that we
care about the treatment effect for the “compliers”
because this is the only subset of the population
whose treatment behaviors are modifiable. This ra-
tionale is problematic, however, as the definition of
“compliers” is instrument-dependent (Pearl, 2011).
If multiple instruments were separately used to es-
timate the effect of treatment in the “compliers” in
the same study, each effect estimate would be per-
tinent to a different subset of the population: the
“compliers” are different for each IV analysis. It is
unclear why the effects in all these various subsets
would be of primary interest. The perception of the
“compliers” being the subset whose behaviors are
modifiable is overly simplistic because it ignores this
instrument dependence.
Other authors, like Imbens in his review, perceive
the LATE as a “second choice” estimand, yet ad-
vocate it can sometimes be useful. He argues for
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reporting subgroup effects even if the subgroup-
specific analysis is not exactly addressing the pri-
mary research question. He proposes an analogy be-
tween estimating the effect in the “compliers” and
estimating an effect in an all-male randomized trial,
where males are, like “compliers,” a subset of the
general population. This analogy begs the question:
why would we be interested in the effect estimate
from a male-only trial? There are two possible rea-
sons: (1) we wish to inform clinical or policy de-
cisions for men only, or (2) we wish to extrapo-
late from the study to inform decisions for men and
women. If the former, the analogy with the “com-
pliers” seems ill-placed: as we do not know who is
a “complier,” we would not know to whom our new
policy should apply. If the latter, then we would
need to assume effect homogeneity between men and
women. However, in IV analyses, the LATE is often
chosen over the global ATE precisely because we ex-
pect too much effect heterogeneity for the ATE to
be validly identified. As such, extrapolation of the
LATE to the entire population could be ill-advised.
Finally, the LATE does not naturally translate
to time-varying treatments. Because many if not
most exposures studied in epidemiologic research
vary over time, we cannot rely on the LATE to
meaningfully study their effects. If we want to study
the effects of time-varying treatments or exposures
within the IV framework, we may instead con-
sider g-estimation of structural nested models. This
approach requires detailed modeling assumptions
about the effect of treatment (Robins and Herna´n,
2009).
2. PLAUSIBILITY OF MONOTONICITY IN
EPIDEMIOLOGIC RESEARCH
Part of the argument for favoring the LATE is
that the requisite monotonicity assumption appears
more reasonable than the homogeneity assumptions
required to estimate the “global” ATE. For dichoto-
mous treatments and instruments, monotonicity re-
quires no “defiers” exist, while homogeneity requires
there is no effect modification by the instrument
among the treated and untreated (Robins, 1989).
However, while it may be plausible that there are
essentially zero “defiers” in a randomized trial, the
monotonicity condition may not hold for instru-
ments used in observational studies.
Consider one of the most commonly proposed in-
struments in epidemiologic research, physician or fa-
cility prescribing preference (Swanson and Herna´n,
2013). Suppose we are interested in estimating the
effect of a specific treatment relative to no treat-
ment among patients attending a clinic where two
physicians with different preferences work. The first
physician usually prefers to prescribe the treatment,
but she makes exceptions for her patients with di-
abetes (because of some known contraindications).
The second usually prefers to not prescribe the
treatment, but he makes exceptions for his more
physically active patients (because of some per-
ceived benefits). Any patient who was both phys-
ically active and diabetic would have been treated
contrary to both of these physicians preferences and,
therefore, would be a “defier.” Because physicians’
preferences represent the weighing of a variety of
risks and benefits, there may be many opportuni-
ties for a patient to be treated contrary to physi-
cians’ preferences, and thus exhibit a violation of
monotonicity (Swanson et al., 2014a).
Moreover, the compliance types (“compliers,”
“defiers,” “always-takers,” “never-takers”) are not
well-defined for such instruments. Our example
above considers a study with only two physicians
that could possibly have seen our patients. In more
common research settings with multiple physicians,
for the compliance types to be well-defined, all
physicians with the same level of preference who
could have seen a patient would have to then treat
the patient in the exact same way. Because this is
unrealistic, not only is it more likely that there are
monotonicity violations but whoever the “compli-
ers” are that our effect pertains to is not just an
unidentifiable but an ill-defined subset of our popu-
lation (Swanson et al., 2014a).
Further, most of the commonly proposed instru-
ments in epidemiologic research use a noncausal
proxy instrument in their analyses. This is done
out of necessity, for example, we cannot measure
the actual preference of the physician when using a
preference-based instrument, or we sometimes only
have the means to measure approximate locations in
the genome when using a genetic-based instrument.
Although the use of such a noncausal instrument
could satisfy the other identifying assumptions, this
measurement error complicates our interpretation
of a LATE-like effect (Herna´n and Robins, 2006).
In particular, if the unmeasured causal instrument
is continuous, then the standard IV estimator us-
ing a dichotomous proxy instrument would not be
an effect in a specific “compliant” subpopulation
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but rather identifies a weighted average of every-
body with weights that are not particularly mean-
ingful to any policy decision. This is assuming that
monotonicity held for the unmeasured causal instru-
ment, which is unlikely for instruments like prefer-
ence where the instrument is a summary of mul-
tiple dimensions of encouragement (Swanson et al.,
2014a).
3. ALTERNATIVE APPROACHES:
A REFOCUS ON THE GLOBAL AVERAGE
TREATMENT EFFECT
Because the LATE is not generally relevant to
epidemiologic research questions, and the appar-
ently plausible monotonicity assumption is actu-
ally implausible in many common settings, we
suggest shifting focus back to the effect of pri-
mary interest, which is often the global ATE
(Robins and Greenland, 1996). Imbens summarized
two options for this using IV methods: (1) present
bounds for the ATE (Balke and Pearl, 1997), which
are often too wide to directly inform the particular
decision at hand, or (2) present a point estimate
for the ATE assuming effect homogeneity (Robins,
1994), even though this assumption often is not
palatable. Of course this dichotomy is somewhat
artificial: we can always do both. Moreover, there
are middle grounds.
Consider the canonical flu vaccine trial that
Imbens described: physicians were randomized
to either receive or not receive a letter encourag-
ing influenza vaccinations for their patients, and we
are interested in the effect of vaccination on flu-re-
lated hospitalizations (McDonald, Hui and Tierney,
1992). Under the instrumental conditions but not
monotonicity, Imbens calculated the Balke–Pearl
bounds of [−0.24, 0.64] for the global ATE. These
bounds do not allow us to conclude whether vaccines
are incredibly helpful, harmful, or somewhere in be-
tween. If we further assume effect homogeneity, the
point estimate is −0.12 using the standard IV esti-
mator that assumes additive homogeneity. However,
these homogeneity assumptions are often perceived
as too strong. Next, we propose a middle ground
between the uninformative bounds based on reason-
able assumptions (at least in the flu vaccine trial)
and the point estimate based on the often heroic
assumption of homogeneity.
One reason the Balke–Pearl bounds are often wide
is because (by definition) we have no information on
what would have happened to the always-takers had
they not been vaccinated and what would have hap-
pened to the never-takers had they been vaccinated.
The bounds are estimated under the most extreme
scenarios where all or none of these patients would
be hospitalized under these unobserved counterfac-
tual treatments. However, we could use subject-
matter knowledge to assume a more reasonable
range of possibilities. For example, we might pro-
pose that at most 10% of the never-takers un-
der treatment and 10% of the always-takers un-
der no treatment would be hospitalized. We can
then use extensions of the Balke–Pearl bounds to
estimate bounds of [−0.07, 0.02] that are consis-
tent with this further constraint and monotonic-
ity (Richardson and Robins, 2010). If our narrower
bounds are correct, the estimated LATE using the
standard IV estimator under monotonicity (−0.12)
overstates the benefit of vaccination that would have
occurred had we vaccinated the whole population. If
we assume stricter limits on what would have hap-
pened to the never-takers under treatment (e.g., at
most 5% would have been hospitalized), we can nar-
row the bounds and identify the direction of the ef-
fect: [−0.07, −0.02]. A disadvantage of this approach
is that, like approaches based on estimating the
LATE, it requires well-defined compliance types, an
assumption that may be reasonable for this random-
ized trial but less appropriate in other settings as we
detailed above. For a review of other approaches to
partial identification of the global ATE under IV-
type assumptions, see Swanson et al. (2014b).
Another middle ground approach is to describe
the sensitivity of the point estimate to the suspected
effect heterogeneity. A problem with this approach
is that the homogeneity condition is mathemati-
cally stated with respect to the instrument, which
is not intuitive, and thus makes it difficult to ap-
ply subject-matter knowledge toward understanding
the validity of the condition. To solve this problem,
Herna´n and Robins (2006) proposed a sufficient con-
dition for heterogeneity that is stated with respect
to the confounders. This sufficient condition allows
us to use subject matter knowledge to understand
its plausibility—and, therefore, we can also propose
sensitivity analyses based on plausible violations of
this assumption. An advantage of this approach is
we no longer need to assume the compliance types
are well-defined or of a known distribution. Some
authors have previously proposed ways to under-
stand the implications of measured effect modifiers
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(Brookhart and Schneeweiss, 2007), and these ideas
could be extended to consider unmeasured effect
modifiers as well.
4. CONCLUSION
Imbens states we are “limited in the questions
we can answer credibly and precisely.” We agree,
but there are differences between the questions
we can answer and the questions we want an-
swered. Choosing only answerable questions (e.g.,
identifying the LATE in some settings) can mislead
decision-making efforts: our estimates may be mis-
interpreted as directly relevant to a decision when in
fact they are only tangentially related. On the other
hand, exact answers for our questions (e.g., identi-
fying the global ATE) may be often unattainable,
but a combination of data and assumptions based
on subject-matter knowledge may go a long way to-
wards partly answering them (e.g., obtaining narrow
bounds for the ATE). At the very least, incomplete
answers should serve as a reminder and encourage-
ment that further studies—using other data and/or
other assumptions—are warranted.
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